Terms: = Liver cancer AND SEPT9, PNUTL4, 10801, ENSG00000184640, MSF1, KIAA0991, AF17q25, MSF, SeptD1, SINT1 AND Treatment
5 results:
1. Ultrasensitive and Quantitative DNA Methylation Detection Method Based on the MutS Protein.
Zhang L; Zhang W; Mu Y; Hu H; Dong K; Wen X; Ye Z; Sun Q; Yan B; Mao Z; Xiao X
Anal Chem; 2023 Dec; 95(51):18828-18835. PubMed ID: 38078896
[TBL] [Abstract] [Full Text] [Related]
2. Methylated sept9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma.
Saeki I; Suehiro Y; Yamauchi Y; Hoshida T; Tanabe N; Oono T; Kawamoto D; Nishimura T; Matsumoto T; Ishikawa T; Shimokawa M; Tamori A; Kawada N; Tamai Y; Iwasa M; Nakagawa H; Nagano H; Takami T; Yamasaki T
Hepatol Int; 2023 Oct; 17(5):1289-1299. PubMed ID: 37186217
[TBL] [Abstract] [Full Text] [Related]
3. msept9 Can Monitor the Response and Predict the Prognosis of Stage IV Colorectal cancer Patients with liver Metastasis Undergoing Potentially Curative Surgery.
Liu W; Hu P; Liu J; Chen L
J Surg Res; 2021 Nov; 267():485-494. PubMed ID: 34246842
[TBL] [Abstract] [Full Text] [Related]
4.
Li B; Huang H; Huang R; Zhang W; Zhou G; Wu Z; Lv C; Han X; Jiang L; Li Y; Li B; Zhang Z
Dis Markers; 2020; 2020():6289063. PubMed ID: 33178361
[TBL] [Abstract] [Full Text] [Related]
5. Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal cancer liver Metastasis.
Bhangu JS; Beer A; Mittlböck M; Tamandl D; Pulverer W; Schönthaler S; Taghizadeh H; Stremitzer S; Kaczirek K; Gruenberger T; Gnant M; Bergmann M; Mannhalter C; Weinhäusel A; Oehler R; Bachleitner-Hofmann T
Ann Surg; 2018 Nov; 268(5):894-902. PubMed ID: 30080722
[TBL] [Abstract] [Full Text] [Related]
